Comparison analysis of PD-1/PD-L1 inhibitors plus lenvatinib or gemcitabine/cisplatin as first-line treatment for patients with advanced intrahepatic cholangiocarcinoma

BackgroundIntrahepatic cholangiocarcinoma (ICC) is a highly aggressive primary liver cancer, with increasing incidence worldwide. Effective first-line treatments for advanced ICC patients are currently limited. Therefore, our study aimed to assess the efficacy and safety of programmed death-1 (PD-1)...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Jia-Xin Huang, Bo Liu, Yu Li, Xi Li, Li-Juan Ding, Nan-Ya Wang
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Frontiers Media S.A. 2023-08-01
סדרה:	Frontiers in Oncology
נושאים:	intrahepatic cholangiocarcinoma PD-1/L1 lenvatinib gemcitabine plus cisplatin advanced cancer
גישה מקוונת:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1204486/full
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!